SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals reports 30% rise in Q4 consolidated net profit

27 Apr 2016 Evaluate

Alembic Pharmaceuticals has reported results for the fourth quarter and year ended March 31, 2016. 

The company has posted a rise of 32.69% its net profit at Rs 89.02 crore for the quarter ended March 31, 2016 as compared to Rs 67.09 crore for the same quarter in the previous year. Total income of the company has increased by 19.65% at Rs 590.96 crore for quarter under review as compared to Rs 493.92 crore for the quarter ended March 31, 2015.

On consolidated basis, the company has posted a rise of 29.65% in its net profit after taxes and share of profit of associates at Rs 91.18 crore for the quarter ended March 31, 2016 as compared to Rs 70.33 crore for the corresponding quarter in the FY15. Total income of the company rose 24.63% at Rs 629.19 crore for quarter under review as compared to Rs 504.83 crore for the same quarter ended previous year.

For the year ended March 31, 2016, the company has posted over two fold jump in its net profit at Rs 698.13 crore as compared to Rs 286.61 crore for the same period in the previous year. Total income of company increased 48.41% at Rs 2997.25 crore for year under review as compared to Rs 2019.57 crore for the period ended March 31, 2015.

For the year ended March 31, 2016, on the consolidated basis, the company has posted over two fold jump in its net profit after taxes and share of profit of associates at Rs 719.44 crore as compared to Rs 282.93 crore for the same period in the previous year. Total income of company has increased by 53.24% at Rs 3154.22 crore for year under review as compared to Rs 2058.42 crore for the period ended March 31, 2015.  

Alembic Pharma Share Price

759.00 -25.95 (-3.31%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×